|
1
|
International Agency for Research on
Cancer: Estimated number of incident cases, both sexes, worldwide
(top 10 cancer sites) in 2012. 2012.http://gco.iarc.fr/today/online-analysis-multi-bars?mode=cancer&mode_population=continents&population=900&sex=0&cancer=29&type=0&statistic=0&prevalence=0&color_palette=defaultSeptember
11–2018
|
|
2
|
International Agency for Research on
Cancer: Estimated number of deaths, both sexes, worldwide (top 10
cancer sites) in 2012. 2012.http://gco.iarc.fr/today/online-analysis-multi-bars?mode=cancer&mode_population=continents&population=900&sex=0&cancer=29&type=1&statistic=0&prevalence=0&color_palette=defaultSeptember
11–2018
|
|
3
|
Wagner AD, Unverzagt S, Grothe W, Kleber
G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev. 3:CD0040642010.
|
|
4
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Szkandera J, Stotz M, Absenger G,
Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R, Alzoughbi
W, Lackner C, Ress AL, et al: Validation of C-reactive protein
levels as a prognostic indicator for survival in a large cohort of
pancreatic cancer patients. Br J Cancer. 110:183–188. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McMillan DC, Forrest LM, O'Gorman P,
Angerson WJ and McArdle CS: Performance status of male and female
advanced cancer patients is independently predicted by mid-upper
arm circumference measurement. Nutr Cancer. 42:191–193. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wei Y, Jiang YZ and Qian WH: Prognostic
role of NLR in urinary cancers: A meta-analysis. PLoS One.
9:e920792014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Imrie CW: Host systemic inflammatory
response influences outcome in pancreatic cancer. Pancreatology.
15:327–330. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Charlson ME, Pompei P, Ales KL and
MacKenzie CR: A new method of classifying prognostic comorbidity in
longitudinal studies: Development and validation. J Chronic Dis.
40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sano T and Aiko T: New Japanese
classifications and treatment guidelines for gastric cancer:
Revision concepts and major revised points. Gastric Cancer.
14:97–100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aapro MS, Köhne CH, Cohen HJ and Extermann
M: Never too old? Age should not be a barrier to enrollment in
cancer clinical trials. Oncologist. 10:198–204. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hutchins LF, Unger JM, Crowley JJ, Coltman
CA Jr and Albain KS: Underrepresentation of patients 65 years of
age or older in cancer-treatment trials. N Engl J Med.
341:2061–2067. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Monfardini S, Sorio R, Boes GH, Kaye S and
Serraino D: Entry and evaluation of elderly patients in European
Organization for Research and Treatment of Cancer (EORTC)
new-drug-development studies. Cancer. 76:333–338. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giovanazzi-Bannon S, Rademaker A, Lai G
and Benson AB III: Treatment tolerance of elderly cancer patients
entered onto phase II clinical trials: An Illinois Cancer Center
study. J Clin Oncol. 12:2447–2452. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ajani JA, Rodriguez W, Bodoky G,
Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A,
Lang I and Falcon S: Multicenter phase III comparison of
cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced
gastric or gastroesophageal adenocarcinoma study: The FLAGS trial.
J Clin Oncol. 28:1547–1553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koizumi W, Akiya T, Sato A, Sakuyama T,
Sasaki E, Tomidokoro T, Hamada T, Fujimori M, Kikuchi Y, Shimada K,
et al: Phase II study of S-1 as first-line treatment for elderly
patients over 75 years of age with advanced gastric cancer: The
Tokyo Cooperative Oncology Group study. Cancer Chemother Pharmacol.
65:1093–1099. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Imamura H, Kishimoto T, Takiuchi H, Kimura
Y, Morimoto T, Imano M, Iijima S, Yamashita K, Maruyama K, Otsuji
T, et al: Phase II study of S-1 monotherapy in patients over 75
years of age with advanced gastric cancer (OGSG0404). J Chemother.
26:57–61. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang X, Zhang W and Feng LJ: Prognostic
significance of neutrophil lymphocyte ratio in patients with
gastric cancer: A meta-analysis. PLoS One. 9:e1119062014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hwang JE, Kim HN, Kim DE, Choi HJ, Jung
SH, Shim HJ, Bae WK, Hwang EC, Cho SH and Chung IJ: Prognostic
significance of a systemic inflammatory response in patients
receiving first-line palliative chemotherapy for recurred or
metastatic gastric cancer. BMC Cancer. 11:4892011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Namikawa T, Munekage E, Munekage M, Maeda
H, Yatabe T, Kitagawa H, Kobayashi M and Hanazaki K: Evaluation of
systemic inflammatory response biomarkers in patients receiving
chemotherapy for unresectable and recurrent advanced gastric
cancer. Oncology. 90:321–326. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arai T, Esaki Y, Inoshita N, Sawabe M,
Kasahara I, Kuroiwa K, Honma N and Takubo K: Pathologic
characteristics of gastric cancer in the elderly: A retrospective
study of 994 surgical patients. Gastric Cancer. 7:154–159. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang JY, Hsieh JS, Huang CJ, Huang YS and
Huang TJ: Clinicopathologic study of advanced gastric cancer
without serosal invasion in young and old patients. J Surg Oncol.
63:36–40. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hashimoto H, Esaki Y, Kino K, Takahashi T
and Takubo K: Gastric cancer in the elderly - relationship between
macroscopic appearance and histological type in autopsy specimens.
Nippon Ronen Igakkai Zasshi. 34:499–505. 1997.(In Japanese).
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mizoe A, Tanaka K, Ura K, Izawa K, Tsunoda
T and Kanematsu T: Long term prognosis according to histological
type of gastric cancer. J Jpn Pract Surg Soc. 54:1732–1737.
1993.(In Japanese).
|
|
26
|
Forrest LM, McMillan DC, McArdle CS,
Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic
scores based on the systemic inflammatory response in patients with
inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Osugi J, Muto S, Matsumura Y, Higuchi M,
Suzuki H and Gotoh M: Prognostic impact of the high-sensitivity
modified Glasgow prognostic score in patients with resectable
non-small cell lung cancer. J Cancer Res Ther. 12:945–951. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Decoster L, Van Puyvelde K, Mohile S,
Wedding U, Basso U, Colloca G, Rostoft S, Overcash J, Wildiers H,
Steer C, et al: Screening tools for multidimensional health
problems warranting a geriatric assessment in older cancer
patients: An update on SIOG recommendations. Ann Oncol. 26:288–300.
2015. View Article : Google Scholar : PubMed/NCBI
|
